Revance TherapeuticsRVNC
RVNC
About: Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
Employees: 597
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
103% more capital invested
Capital invested by funds: $212M [Q2] → $430M (+$219M) [Q3]
58% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 45
15% more funds holding
Funds holding: 172 [Q2] → 198 (+26) [Q3]
0.8% more ownership
Funds ownership: 78.86% [Q2] → 79.66% (+0.8%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
17% less call options, than puts
Call options by funds: $4.42M | Put options by funds: $5.33M
28% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 54
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$3
2%
downside
Avg. target
$4.23
38%
upside
High target
$6.60
115%
upside
3 analyst ratings
0 positive
0%
3 neutral
100%
0 negative
0%
Barclays Balaji Prasad 45% 1-year accuracy 20 / 44 met price target | 2%downside $3 | Equal-Weight Maintained | 23 Dec 2024 |
Mizuho Vamil Divan 30% 1-year accuracy 6 / 20 met price target | 1%upside $3.10 | Neutral Maintained | 10 Dec 2024 |
HC Wainwright & Co. Douglas Tsao 40% 1-year accuracy 66 / 167 met price target | 115%upside $6.60 | Neutral Reiterated | 8 Nov 2024 |
Financial journalist opinion
Based on 7 articles about RVNC published over the past 30 days
Neutral
Business Wire
6 days ago
REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNC
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Revance Therapeutics, Inc. (NasdaqGM: RVNC) to Crown Laboratories, Inc. Under the terms of the proposed transaction, shareholders of Revance will receive $3.10 in cash for each share of Revance that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or.
Neutral
Business Wire
1 week ago
Shareholder Alert: Ademi LLP Investigates Whether Revance Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Revance (NASDAQ: RVNC) for possible breaches of fiduciary duty and other violations of law in its transaction with Crown. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the revised transaction, Revance stockholders will receive only $3.10 per share in cash, less than one-half of the August 2024 purc.
Neutral
PRNewsWire
1 week ago
Crown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.10 per share
Board of Directors of Revance Recommend Stockholders Tender their Shares JOHNSON CITY, Tenn. , Dec. 12, 2024 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced that it has commenced a cash tender offer to acquire all outstanding shares of common stock of Revance Therapeutics, Inc., ("Revance") (Nasdaq: RVNC) at a price of $3.10 per share in cash.
Negative
Reuters
2 weeks ago
Revance agrees to lower-priced buyout offer by Crown Laboratories
Anti-wrinkle injection maker Revance Therapeutics has agreed to be bought for $3.10 per share by privately held Crown Laboratories, instead of $6.66 per share agreed previously, the two companies said on Monday.
Neutral
PRNewsWire
2 weeks ago
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
JOHNSON CITY, Tenn. and NASHVILLE, Tenn.
Neutral
Business Wire
2 weeks ago
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
JOHNSON CITY & NASHVILLE, Tenn.--(BUSINESS WIRE)--Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement.
Neutral
GlobeNewsWire
3 weeks ago
Hyaluronic Acid Market Report 2024, Featuring Profiles of Allergan, Galderma, Revance Therapeutics, Hyaluronic Acid Manufacturing Co. and Fidia Farmaceutici - Forecasts to 2029
The hyaluronic acid market is poised for substantial growth over the coming years driven by its diverse applications, increasing consumer demand for beauty and wellness products, and advancements in manufacturing technologies. The hyaluronic acid market is poised for substantial growth over the coming years driven by its diverse applications, increasing consumer demand for beauty and wellness products, and advancements in manufacturing technologies.
Neutral
Accesswire
1 month ago
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about Securities Fraud Investigation - RVNC
NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".
Neutral
PRNewsWire
1 month ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
NEW YORK , Nov. 10, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Accesswire
1 month ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Charts implemented using Lightweight Charts™